1. Food and Drug Administration. COVID-19 vaccines: COVID-19 vaccines authorized for emergency use or FDA-approved. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2023. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines
2. Interim recommendations from the Advisory Committee on Immunization Practices for the use of bivalent booster doses of COVID-19 vaccines—United States, October 2022.;Rosenblum;MMWR Morb Mortal Wkly Rep,2022
3. Link-Gelles R. COVID-19 vaccine effectiveness updates. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; April 19, 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-04-19/05-COVID-Link-Gelles-508.pdf
4. Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions—VISION Network, September 2022–April 2023.;Link-Gelles;MMWR Morb Mortal Wkly Rep,2023
5. Food and Drug Administration. FDA briefing document: future vaccination regimens addressing COVID-19. Presented at the Vaccines and Related Biological Products Advisory Committee meeting, Silver Spring, MD; January 26, 2023. https://www.fda.gov/media/164699/download